1. Home
  2. DMLP vs TYRA Comparison

DMLP vs TYRA Comparison

Compare DMLP & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DMLP

Dorchester Minerals L.P.

HOLD

Current Price

$25.52

Market Cap

1.1B

Sector

Energy

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$30.62

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMLP
TYRA
Founded
2003
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DMLP
TYRA
Price
$25.52
$30.62
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$38.83
AVG Volume (30 Days)
171.1K
646.3K
Earning Date
02-19-2026
11-05-2025
Dividend Yield
10.99%
N/A
EPS Growth
N/A
N/A
EPS
1.13
N/A
Revenue
$143,803,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$22.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.85
$6.42
52 Week High
$32.47
$32.44

Technical Indicators

Market Signals
Indicator
DMLP
TYRA
Relative Strength Index (RSI) 73.77 61.88
Support Level $23.35 $28.51
Resistance Level $25.83 $32.39
Average True Range (ATR) 0.60 1.93
MACD 0.22 -0.08
Stochastic Oscillator 87.33 63.99

Price Performance

Historical Comparison
DMLP
TYRA

About DMLP Dorchester Minerals L.P.

Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: